Sale!

SLC35A1 Gene Glycosylation Disorder Type 2F Genetic Test

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The SLC35A1 gene glycosylation disorder, also known as Congenital Disorder of Glycosylation Type 2F (CDG2F), is a rare genetic condition characterized by defects in the glycosylation process. Glycosylation is a critical biological process where sugars are attached to proteins and lipids, affecting their stability and function. Mutations in the SLC35A1 gene disrupt this process, leading to a wide range of symptoms, including developmental delay, neurological issues, and problems with the digestive system.

To diagnose this condition, a genetic test focusing on the SLC35A1 gene can be conducted. In the United Arab Emirates, DNA Labs UAE offers this specialized test. The test is designed to identify mutations in the SLC35A1 gene that are responsible for the glycosylation disorder Type 2F. The cost of the test is 4400 AED, making it accessible to those who suspect they or their family members might be affected by this rare genetic disorder. Conducting the test can provide crucial information for the diagnosis, management, and treatment of the condition, helping affected individuals and their families to navigate the challenges associated with CDG2F.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

SLC35A1 Gene Glycosylation disorder type 2F Genetic Test

Components: SLC35A1 Gene Glycosylation disorder type 2F Genetic Test

Price: 4400.0 AED

Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card

Report Delivery: 3 to 4 Weeks

Method: NGS Technology

Test Type: Neurological Disorders

Doctor: Neurologist

Test Department: Genetics

Pre Test Information: Clinical History of Patient who is going for SLC35A1 Gene Glycosylation disorder type 2F NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with SLC35A1 Gene Glycosylation disorder type 2F.

Test Details

The SLC35A1 gene is associated with glycosylation disorder type 2F, also known as congenital disorder of glycosylation type 2F (CDG2F). This genetic disorder affects the body’s ability to produce and attach sugar molecules to proteins, which can cause a wide range of symptoms including developmental delays, intellectual disability, seizures, and abnormal facial features.

NGS (next-generation sequencing) genetic testing is a type of DNA testing that can analyze multiple genes at once, quickly and accurately. A NGS genetic test for the SLC35A1 gene can identify any variations or mutations in the gene that may be causing CDG2F. This information can help healthcare providers diagnose the disorder and provide appropriate treatment and management strategies for affected individuals.

Test Name SLC35A1 Gene Glycosylation disorder type 2F Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card o
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Neurological Disorders
Doctor Neurologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for SLC35A1 Gene Glycosylation disorder type 2F NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with SLC35A1 Gene Glycosylation disorder type 2F
Test Details

The SLC35A1 gene is associated with glycosylation disorder type 2F, also known as congenital disorder of glycosylation type 2F (CDG2F). This genetic disorder affects the body’s ability to produce and attach sugar molecules to proteins, which can cause a wide range of symptoms including developmental delays, intellectual disability, seizures, and abnormal facial features.

NGS (next-generation sequencing) genetic testing is a type of DNA testing that can analyze multiple genes at once, quickly and accurately. A NGS genetic test for the SLC35A1 gene can identify any variations or mutations in the gene that may be causing CDG2F. This information can help healthcare providers diagnose the disorder and provide appropriate treatment and management strategies for affected individuals.